Ventilation Support May Explain Why African American ALS Patients Live Longer
Rates of invasive assisted ventilation are 3.2 times higher in African Americans with amyotrophic lateral sclerosis (ALS) compared to Caucasian…
Patricia holds her PhD in cell biology from the University Nova de Lisboa, Portugal, and has served as an author on several research projects and fellowships, as well as major grant applications for European agencies. She also served as a PhD student research assistant in the Department of Microbiology & Immunology, Columbia University, New York, for which she was awarded a Luso-American Development Foundation (FLAD) fellowship.
At Bionews we’re committed to providing the most accurate, relevant, and up-to-date reporting for our patient communities. Our goal is to ensure that everyone has access to disease-specific information that is both trustworthy and easy to understand. You can read more about our editorial policy here.
Rates of invasive assisted ventilation are 3.2 times higher in African Americans with amyotrophic lateral sclerosis (ALS) compared to Caucasian…
Long-term mercury exposure over a period of years may increase the risk of amyotrophic lateral sclerosis later (ALS) in life,…
Magnetic resonance imaging (MRI) may help detect muscle damage in amyotrophic lateral sclerosis (ALS) patients, in particular muscles that are…
Biochemist Dorothee Dormann, PhD, at the Ludwig Maximilians University, in Munich, was awarded the 2019 Paul Ehrlich and…
Occupational exposure to silica is linked to a significantly increased risk of amyotrophic lateral sclerosis (ALS), a population-based study suggests.
Loss of normal ion flow in the skeletal muscle may worsen symptoms of amyotrophic lateral sclerosis (ALS), a mouse study…
Loss of a protein known as ubiquilin causes defects in degradation centers called lysosomes, promoting the buildup of brain waste…
A gene therapy designed to block the activity of SARM1 protein prevented the loss of axons — long projections that connect…
Amyotrophic lateral sclerosis (ALS) patients who complete the ongoing Phase 3 REFALS clinical trial evaluating levosimendan (also known as ODM-109)…
The loss of a key enzyme, called adenosine deaminase, in astrocytes — the energy-supporting cells of neurons — leads to…